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A bst r act
Background: Pathologists and informaticians are becoming increasingly interested in
electronic clinical decision support for pathology,laboratory medicine and clinical diagnosis.
Improved decision support may optimize laboratory test selection, improve test result
interpretation and permit the extraction of enhanced diagnostic information from existing
laboratory data. Nonetheless, the Àeld of pathology decision support is still developing.To
facilitate the exchange of ideas and preliminary studies, we convened a symposium entitled:
Pathology data integration and clinical decision support. Met hods: The symposium was
held at the Massachusetts General Hospital, on May 10, 2013. Participants were selected
to represent diverse backgrounds and interests and were from nine different institutions in
eight different states.Result s:The day included 16 plenary talks and three panel discussions,
together covering four broad areas. Summaries of each presentation are included in this
manuscript. Conclusions: A number of recurrent themes emerged from the symposium.
Among the most pervasive was the dichotomy between diagnostic data and diagnostic
information, including the opportunities that laboratories may have to use electronic
systems and algorithms to convert the data they generate into more useful information.
Differences between human talents and computer abilities were described; well designed
symbioses between humans and computers may ultimately optimize diagnosis. Another
key theme related to the unique needs and challenges in providing decision support for
genomics and other emerging diagnostic modalities. Finally, many talks relayed how the
barriers to bringing decision support toward reality are primarily personnel, political,
infrastructural and administrative challenges rather than technological limitations.
Key words: Clinical decision support, genomics, interpretive reporting, machine
learning, test utilization
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IN T RODU CT ION
Pathologists and informaticians are becoming increasingly
interested in the application of electronic clinical
decision support to pathology and laboratory medicine.
Application of decision support has great potential to
optimize laboratory test selection, improve test result
interpretation and permit the extraction of enhanced
diagnostic information from existing laboratory data.[1-3]
This may in turn help to transform laboratory medicine
from primarily an observational field to one more
centered on interpretation and definitive, comprehensive
and precise diagnosis. Anatomic pathology has similar
potential to enhance the diagnostic information it
delivers.
This transformation of pathology may not only help
reduce the waste or errors frequently associated with
laboratory test selection and result interpretation,[1,4-7]
but may also enable a previously unattainable level of
diagnostic precision. Advances in laboratory automation,
next generation sequencing, mass spectrometry and other
emerging data acquisition modalities will surely enhance
laboratory efficiency and diagnostic value. However,
substantial improvements in the diagnostic value of
laboratory tests will also likely result from more effective
use and interpretation of data from traditional assays
and existing technologies. Clinical decision support for
test selection [1,8] and test result interpretation [9] may
help to avoid unnecessary testing, ensure correct tests
are ordered and avoid misinterpretation of test results.
Moreover, application of statistical, computational and
machine-learning techniques to clinical and laboratory
data may reveal key patterns and insights that manual
interpretation of the data could not.[2,3] In fact, many of
the barriers to expanding the clinical application of next
generation sequencing and other diagnostic modalities
lie not in the data collection, but in the analysis and
interpretation.[10]
Transforming the focus of pathology and laboratory
medicine to more broadly emphasize data analysis and
personalized diagnosis may also be of key importance
in maintaining the relevance of the specialty and
enhancing the value of laboratory testing. In particular,
expanding use of automation is leading to an increased
perception that certain routine laboratory services can
be thought of as commodities with cost being the only
real consideration.[11,12] A key strategy for overcoming
such commoditization of laboratory services will be to
understand that even if generation of certain laboratory
data becomes routine, the process of extracting useful
diagnostic information from this data will become
increasingly complex.[13] Laboratories and pathology
services could shift their primary focus from creating
data to generating diagnostic, prognostic and therapeutic
information.[1,9,13,14] Furthermore, particularly with
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increased emphasis on cost-containment and utilization
management, compounded by an increase in the
complexity of testing (such as genomic analyses), it will
be increasingly important for laboratories to assist with
test selection.[15,16] Computational data analysis and
decision support systems will almost certainly be integral
to this evolution in pathology and laboratory diagnosis.[1,8]
Nonetheless, pathology decision support is still in
its infancy. To facilitate the exchange of ideas and
preliminary studies, we convened a symposium entitled:
Pathology data integration and clinical decision support.
Here we summarize some of the views shared in the
symposium to provide an overview of the current state of
the field and the challenges it faces.

MET H O DS/MEET IN G O RGA N IZAT ION A N D
ST RU CT U RE
The symposium on Pathology data integration and
clinical decision support, held at the Massachusetts
General Hospital (MGH), Boston, MA on May 10, 2013,
was sponsored by the MGH Department of Pathology
and the Partners Fellowship Program in Pathology
Informatics and was organized by JB, AD and JG. The
speakers were selected to provide varied interests and
backgrounds with half of the speakers coming from
within the MGH Department of Pathology and half
from institutions around the country. The 1-day meeting
was divided into four subtopics and included 16 plenary
talks, ranging from 20 to 25 min. The symposium also
included three panel discussions during which questions
from the audience were answered and discussed. This
paper provides a brief summary of each plenary talk. In
addition, the paper concludes with a synthesis of the key
themes of the symposium and provides some “next-steps”
for the field based upon the symposium presentations
and discussions.

RESU LT S

Block 1 Presentations: Big Picture Concepts and
the Need for Pathology Data Integration and
Decision Suppor t
David Louis, MD

The first talk of the day was by David Louis,
Pathologist-in-Chief of the MGH Department of
Pathology and Benjamin Castleman Professor of
Pathology at Harvard Medical School. Dr. Louis’ talk,
“The Skeleton of Computational Pathology,” described
a vision for the future of pathology along with a
“skeleton” of the “computational pathology” efforts
ongoing within the MGH Department of Pathology. In
particular, Dr. Louis first noted that laboratories and
pathologists currently provide clinicians mostly with
relatively discrete elements of diagnostic data, including
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anatomic pathology interpretations, laboratory results
and increasingly, “omics” data. Clinicians then must
interpret this pathology data in the context of the
clinical findings and medical knowledge to arrive at a
diagnosis or treatment plan. However, moving forward,
pathology services may add value by integrating within a
single synthesized report an interpretation of the various
elements of data they produce. The integrated report will
interpret findings and results within the context of the
particular clinical setting, utilizing medical knowledge
derived from databases and medical literature.
Dr. Louis outlined an approach for reaching this goal and
the final product may involve a pipeline containing at least
six components: Clinical data integration, mathematical
biologic modeling, clinical decision support, “omics and
imaging” (algorithmically processing high complexity
datasets), integrated reporting and performance analysis.
In this pipeline, clinical data integration serves as the input
step, integrated reporting is the output step and clinical
decision support, mathematical modeling and “omics” and
imaging comprise the “stuff in the middle,” processing,
integrating and interpreting the data. Performance analysis
will be used to monitor the entire process to identify areas
for improvement, analyze findings in the context of health
care resource utilization and demonstrate the clinical and
economic value of the approach.
Dr. Louis further described the efforts ongoing within
the MGH Department of Pathology to make this vision a
reality. The department has organized six working groups
corresponding to the six components noted above with
over 80 members of the pathology department (faculty
and trainees) participating in at least one working group.
At the current time, the groups are carrying out analyses
and designing projects in their assigned area. A steering
committee that includes the chairpersons of each working
group meets periodically to coordinate and integrate the
work and activities across all six groups. Department-wide
meetings in computational pathology occur about every
6 months and are intended to update the faculty and
trainees, to get further input from members of all working
groups and to encourage other faculty and trainees to
join the overall effort.

Brian Jackson, MD
Following Dr. Louis’ talk emphasizing the “what,”
Brian Jackson, Chief Medical Informatics Officer
at ARUP Laboratories and Associate Professor of
Pathology (Clinical) at the University of Utah helped
to elucidate the “why.” His talk, “The Psychology of
Decision Making: W hy Don’t Those Darned Doctors Use
Our Tests Properly?” introduced two important ideas:
1. The human brain is ineffective at deriving
information from multidimensional data (i.e., many
discrete elements such as with a set of many
laboratory values from the same patient).
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2.

The brain is poor at “meta-cognition” and people
often do not have accurate insight into why they
make certain decisions. Similarly, the confidence
that people place in the decisions or predictions they
make may be impacted by factors not particularly
relevant to the decision.

To illustrate these ideas, Dr. Jackson presented
several studies. One small study,[17] first surveyed two
rheumatologists to discover which factors they each
considered most important in assessing disease activity
in rheumatoid arthritis patients. The rheumatologists
were then asked to assess disease activity in a set of
patients based upon chart review. The study found that
the rheumatologists thought that they were putting
significant weight on all five of the factors surveyed when
making their assessments. However, in practice, each
rheumatologist based the assessments almost entirely on
a single factor. Dr. Jackson noted that, to the extent that
this small study is generalizable, the results illustrate that
the physicians may make medical decisions without really
understanding the basis for these decisions.
Dr. Jackson next presented a study of “horserace
handicappers” who attempt to predict the outcomes
of horse races by using various known “predictors.”[18]
This study demonstrated that as the handicappers were
presented with an increasing number of discrete data
elements on which to make predictions (from 5-10
to 20-40) the accuracy of their predictions remained
unchanged, but the confidence in their predictions
increased. To the extent that this horserace study can be
extended to clinical diagnosis, Dr. Jackson concluded that
“flooding doctors with data does not improve diagnostic
accuracy, but it probably contributes to overconfidence.”
At the conclusion of his talk and during a panel
discussion, Dr. Jackson considered the questions of
where the “bottlenecks” are occurring in laboratory-based
diagnosis. In particular, Dr. Jackson argued that we
produce more data than we can currently use; we need
to shift some of our emphasis away from increasing the
availability of new data and toward better applying and
extracting information from the data we already produce.

John Gilbertson, MD
John Gilbertson, Associate Chief for Informatics in the
Department of Pathology at the MGH and Associate
Professor at Harvard Medical School, presented
“Pathology decisions and decision support.” In this talk,
he described some of the technical and administrative
limitations that will need to be overcome to provide
the next generation of decision support and some
solutions currently in progress. Among these challenges
is that laboratory information systems (LIS) traditionally
emphasize the technical aspects of the laboratory while
providing comparatively little support for professional or
interpretive activities. For example, whereas current LIS
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systems support aspects ranging from specimen tracking
to test or special stain ordering to billing, these systems
often provide little more than a word processor for
pathologists to generate interpretive reports. Likewise,
clinical pathology systems often have relatively limited
calculation functionality, significantly hindering the
ability to implement advanced interpretive algorithms.
Molecular LIS modules tend to be particularly limited
with regard to support of professional interpretation.
Dr. Gilbertson proposed that LIS vendors supplement
their traditional “technical LIS” systems by adding to
them “professional LIS systems” with expanded capacity
to facilitate pathologists’ decision making, accurate and
efficient sign out and advanced interpretive algorithms.
With regard to the latter, certain functions may not need
to be directly within the main LIS, but could exist in
external systems; nonetheless, LIS vendors would need
to generate highly flexible application programming
interfaces to enable such external functionality.
Other needs as pathology related clinical decision support
advances include systems for advanced analytics, robust
electronic health records (EHRs), structured, high quality
data, pipelines for molecular and genomic pathology
and infrastructures for data extraction, warehousing
and computation. Tissue registries and digital pathology
systems are other factors that may support various aspects
of research and decision support. A final and perhaps most
significant need are personnel with the skills, knowledge
and desire to advance pathology decision support. This
includes not only highly trained and skilled pathology
informaticians, but also non-informatician pathologists
with informatics literacy. Information technology (IT) and
technical staff with these skills and interests are essential.
Solutions to many of the challenges are being currently
considered in the computational pathology initiative
within the MGH Department of Pathology (see
description of the presentation by David Louis
for additional detail). Other strategies include the
development of informatics faculty consisting primarily of
practicing pathologists (or researchers) with a secondary
practice in informatics and the creation of a large and
robust pathology informatics fellowship training program
to address the personnel needs. MGH pathology is
involved in a co-development agreement with Sunquest
Information Systems to help develop a more advanced
LIS; Dr. Gilbertson is working with Sunquest to expand
the professional LIS functionality of the system.

Stephen Black Schaffer, MD
Stephen Black-Schaffer, Associate Chief for Education
and Training in the Department of Pathology at the
MGH and Associate Professor of Pathology at Harvard
Medical School, presented the final talk of the first block:
“Clinical decision support: Implications for Pathology
Performance Assessment and Trainee Education.” In this
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talk, he addressed how Pathology Departments can use
the comprehensive clinical data they produce to assess
the performance of both the operation as a whole and of
individual pathologists, including trainees. Operational
performance assessment is fundamentally quite similar to
pathologist performance assessment and can use much of
the same data.
In particular, Dr. Black-Schaffer conveyed the perception
that Pathology Departments and Hospitals will increasingly
need to assess and improve operational performance given
increased emphasis on cost containment and shifting
reimbursement models favoring efficiency. “Leakage”
must be avoided. Dr. Black-Schaffer provided an example
of how pathology and laboratory test performance can be
analyzed to optimize the use of molecular testing on fine
needle aspiration specimens taken from thyroid nodules.
Dr. Black-Schaffer also described how the data in the LIS
could be used for performance assessment. In particular,
resident sign-out could be compared with final attending
review to objectively assess how well trainees are meeting
key educational milestones and competencies. However,
to do this in an automated fashion, LIS systems will have
to store preliminary interpretations provided by trainees,
in addition to final reports, in a structured form. A similar
approach could also be used to evaluate peer-review of
pathologist competency.

Block 2 Presentations: Clinical Decision Suppor t
fo r Reso u r ce Ut ilizat io n an d Pio n ee r in g
Diagnostic Modalities Including Genomics and
Systems Biology Based Models
Raskesh Nagarajan, MD, PhD

Rakesh Nagarajan, Associate Professor, Pathology and
Immunology and Associate Professor, Genetics at
Washington University School of Medicine, delivered
the first talk of the second block: “Clinical Genomicist
Workstation: Analyze, interpret and report Nextgen
based molecular diagnostic studies.” He began this talk
by noting the challenges involved in converting genomic
sequencing data into actionable information. Most of
the talk was devoted to describing a platform developed
and used at Washington University in St. Louis to help
overcome some of these challenges. This platform, the
“Clinical Genomicist Workstation,” helps transform raw
sequence data into an interpretive report by processing
data in several tiers. The first tier is “seamless” from
the perspective of the clinical genomicist and automates
basic data processing such as sequencing alignment and
variant calling. Given the clinical application of this
system, this first tier tracks key information that may be
critical to future re-evaluation such as the version of tools
used and parameters specified.
W hereas the first tier focuses on identifying and
calling genomic variants, the second tier begins to
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ascribe meaning to these variants. It applies data from
various genomic databases and knowledge repositories
to identify the subset of variants with known clinical
significance (and which are relevant to the case at hand).
It also provides phenotypic information for these relevant
variants. This step helps to reduce the number of variants
the clinical genomicist must review from an overwhelming
number to a more manageable number and conveniently
provides clinical knowledge about the variants of known
significance. The genomicist workstation also provides
tools for automated clinical report generation and data
visualization.
W hile tiers one and two involve processing data for
individual patients, the third tier serves to curate the
knowledge repository and the rules that can be used to
assign clinical significance to variants. The knowledge
curated in this tier helps to determine which variants
are displayed to the clinical genomicist and under
which circumstances. For example, selection of variants
to display may be tailored to the patient’s test genomic
test order (panel), phenotype, disease or medication list.
Dr. Nagarajan also provided some planned or potential
future enhancements for the system, including sharing of
tier 3 knowledge repositories and rules across institutions.

John Higgins, MD
John Higgins, Assistant Pathologist in the Department
of Pathology at MGH and Assistant Professor in the
Department of Systems Biology at Harvard Medical
School, delivered a talk entitled, “Systems Biology
in Clinical Medicine: Mathematical Model-Based
Diagnosis.” In it, Dr. Higgins argued against the view
held by some that as available data becomes more
expansive, traditional hypothesis-driven mechanistic
biologic and clinical research will become obsolete and
will be replaced by data mining. He suggested to the
contrary that models may be necessary to help make
sense of the data. W hile statistical data mining routines
by themselves are prone to overfitting and may make
differentiating “signal from noise” difficult, placing data
in the context of mechanistic physiologic models helps
constrain the set of hypotheses from that which a raw
statistical approach might use and make true “signal”
easier to identify. Likewise, Dr. Higgins argued that
traditional human clinical intuition alone is inadequate
for optimal interpretation of the large datasets that are
now being developed, because “human intuition doesn’t
scale to multidimensional data” but “human subjective
bias does.”
Dr. Higgins went on to define and describe systems
biology as “the formulation and analysis of mechanistic
models of systems of interacting biological components.”
Models need to be of appropriate detail and complexity
to capture essential patterns, inputs and associations
without being so complex as to be impractical to fit
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and compute and useless for helping us understand how
the biological systems actually work. After discussing
the importance of models, he devoted much of the talk
to providing a specific example of a systems biology
model of the lifecycle of circulating red blood cells
that was derived and validated with existing clinical
laboratory data. The model relies on single-red blood
cell measurements routinely collected on a hematology
analyzer and enables the inference of rates of blood cell
maturation and clearance in the peripheral circulation.
The model allows us to infer and quantify aspects of
pathophysiology that cannot be measured directly and
this additional information may enable earlier and more
accurate diagnosis of conditions such as iron deficiency
anemia. This model, described elsewhere in detail,[19]
provides an important example, illustrating how through
substantive modeling, we can extract substantially
enhanced information from the data we already generate.
Dr. Higgins concluded his talk with a quote from Nobel
Laureate, Sydney Brenner that captured many of the
arguments from the talk: “The orgy of fact extraction
in which everybody is currently engaged has, like most
consumer economies, accumulated a vast debt. This is a
debt of theory and some of us are soon going to have an
exciting time paying it back-with interest, I hope.”[20]

Long Phi Le, MD, PhD
Dr. Long Le, Assistant in Pathology in the Department
of Pathology at the MGH and Assistant Professor of
Pathology at Harvard Medical School, described, in
his talk, “Decision Support for Clinical Genomics,”
the approach that the MGH is taking to develop a
platform for tumor genotyping by next generation
sequencing. Dr. Le argued that tumor therapeutics will
be increasingly targeted to the individual mutational
profile of the patient’s tumor. Like many of the genomics
related talks, Dr. Le’s talk described the shift from the
targeted detection of medically actionable mutations
of known significance to next generation sequencing, a
technique that will lead to the detection of many novel
or rare variants with unknown diagnostic, prognostic and
therapeutic implications.
The current tumor sequencing goal at MGH encompasses
“> 1000 genes (~ 3.6 Mb), × 100 minimum coverage
10 bp into introns, 6-8 Gb of data/tumor-normal pair,
5-10% analytical sensitivity (with regard to tumor
cellularity) and 3-4 week turnaround time.” To help
reach this goal Dr. Le et al. have developed their own
molecular laboratory information management system
termed “Center for Integrated Diagnostics, Wiki,
Laboratory Information Management System”. Based
on the Semantic Mediawiki semantic web technology,
this system supports computerized provider order
entry (CPOE) to allow clinicians to directly input
orders, a key to achieving an effective upfront workflow
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and optimal, accurate test selection in the molecular
diagnostics laboratory. It also supports the full breadth
of the molecular laboratory internal workflow, including
asset tracking (e.g. slides, blocks, nucleic acid extractions
and reagents), slide labeling, assay worksheets, resulting,
reporting, case tracking and document management.
The system is “semi-integrated” with the main anatomic
pathology LIS and has full query functionality of the
stored structured data. Its scalability and capability
for deployment outside of MGH is currently under
investigation. Work to integrate a sequence interpretation
pipeline into this setup is underway with collaboration
from Dr. Gad Getz.
Finally, Dr. Le described a possible variant categorization
scheme for NGS cancer genotyping reporting. Based on
available evidence, variants with actionable treatment
would be classified in the therapeutic category and further
differentiated as “consensus” (based on documented
standard of care consensus guidelines from the Food
and Drug Administration [FDA], College of American
Pathologists, or National Comprehensive Cancer Network)
or “emerging” (based on availability of experimental
drugs reported to be effective in late trials, early trials,
case reports, or preclinical studies). Two other categories
of action ability include “diagnostic” and “prognostic”
markers with strong evidence from the literature. Variants
which do not fall into the above categories but have some
association with cancer pathogenesis would be reported
under mutations with “other relevance.” Finally variants
of clear unknown significance would be grouped by their
functional pathways and reported at the end. Currently,
the laboratory’s Semantic Mediawiki information
management system is being expanded to support the
curation of the variants and also structured reporting for
the MGH cancer genotyping assay.

Brian Shirts, MD, PhD
Brian Shirts, Assistant Professor in the Department of
Laboratory Medicine at the University of Washington,
offered a complementary perspective on the challenges
of providing decision support for genomic testing in his
talk: “Complexity, Uncertainty and Constant Change:
Decision Support for Clinical Next-Gen Sequencing.”
Dr. Shirts began by highlighting an ironic tendency in
laboratory testing: The more stable that a raw laboratory
results is for an individual patient over time, the less
likely it is that the general interpretation guidelines for
that analyte will remain stable. For example, electrolytes
can change rapidly and thus remain relevant for only a
short period of time, but the interpretation guidelines
for electrolytes have remained constant for decades. By
contrast, germline genomic data will not change much
over a patient’s life; however, given the rapidly evolving
state of medical knowledge, the interpretation of a
genetic variant may only remain current for a relatively
short period of time. This irony highlights one of the
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key challenges in genomic testing: Data may need to be
reinterpreted regularly throughout a patient’s life. The
current processes, infrastructure and systems used in
clinical and laboratory diagnosis are not well-adapted to
a future where, even in the absence of new patient data
or clinical changes, a laboratory result may require regular
reinterpretation.
Dr. Shirts noted that the current practice in genomic
data interpretation involves substantial non-automated
interpretation. Genetic counselors are highly valuable in
this regard and can “pay for themselves” by promoting
appropriate and cost effective test utilization. In fact,
a study from ARUP Laboratories demonstrated a very
substantial cost saving attributable to genetic counselors
actively managing genetic test ordering.
Moving forward, the desire will increasingly be to develop
algorithmic and computational approaches to facilitate
the interpretation and application of genomic data.
However, there are inherent statistical limitations that may
prevent automated genetic informatics implementation.
Dr. Shirts used the example of partitioning test reference
ranges based upon genomic information, with a strategy
for doing this previously described in detail,[21] to
illustrate one situation where limitations to integration
of genomic and clinical information can be clearly
illustrated. Another challenge is that many variants are
rare, occurring in only a small portion of the population.
It may be very difficult to determine the significance of
these rare variants, even when they have large effects, due
to the statistical limitations similar to those associated
with finding patterns in multidimensional data when
only a small number of data points are available (see
discussion of overfitting in the talk by Jason Baron).
The field of genomic testing needs automated platforms
for genomic data that integrate structured clinical
data with genomic data that allow for facilitation of
correlation and interpretation. Dr. Shirts stated that
“personalized medicine is about the relationship between
signal and noise,” and it is important for pathologists
to help develop systems that filter the signal (clinically
actionable data) from the noise (inter-individual genetic
variability of no clinical significance).

Craig Mermel, MD, PhD
Craig Mermel, a resident in Clinical Pathology at the
MGH with extensive experience in cancer genomics
research, described some of the infrastructural challenges
that will need to be addressed to facilitate routine
tumor genotyping by next generation sequencing at the
whole-exome or whole-genome levels. In delivering his
talk, “Infrastructure and Reporting Challenges to Clinical
Next-Generation Sequencing Programs,” Dr. Mermel drew
upon and contrasted his experience in tumor genomics at
the Broad Institute, to his experience helping to establish a
next generation sequencing pipeline in the clinical setting.
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In evaluating some of the infrastructure challenges,
Dr. Mermel argued that we need to be aware of several
trends. First, sequencing capacity is expanding much
more rapidly than computational capacity. Sequencing
costs have declined by more than four orders of
magnitude over the past decade to < 10 cents/megabase,
while computational capacity follows roughly “Moore’s
Law” doubling only about every 18-24 months. Currently,
the bottleneck in many aspects of sequence analysis
is computation and the imbalance between ability
to produce sequence data and ability to analyze it is
likely to further exacerbate moving forward. Paralleling
this expansion of sequencing capacity, the number
and types of sequencing platforms is expanding and
shifting (Available from: http://www.omicsmaps.com
for more up to date information) and new algorithmic
techniques are rapidly being developed. Finally, the
knowledge base is rapidly expanding; new mutations of
functional significance are curated every day.
W hile all these aforementioned trends challenge both
research and clinical applications of genomic sequencing,
clinical applications have some additional considerations
that must be addressed. These include requirements to
comply with complex regulations (e.g. Health Insurance
Portability and Accountability Act (HIPAA), Health
Information Technology for Economic and Clinical
Health Act (HITECH), Clinical Laboratory Improvement
Amendments (CLIA), FDA), to interface with clinical
information systems and workflows, to meet clinical
standards with regard to information system stability,
validity and consistency and to provide clinically acceptable
turn-around times.
W hile the field has not solved all of these challenges,
several developments may be inevitable. Foremost,
most of the analysis will need to be automated; manual
evaluation of variants beyond a final report would be
prohibitively expensive. In fact, Dr. Mermel estimated that
a single whole exome sequence would on average have
approximately 500 novel variants, costing at least $2,000
in pathologist time to review (assuming each variant could
be reviewed in 1 min). In addition, it is not feasible for
all institutions and research environments to develop
their own analysis tools. We will need to work together as
community to share tools and even analysis platforms.
Finally, Dr. Mermel argued that we should strongly
consider using cloud architecture for our main sequence
analysis needs. Among the advantages of the “cloud” are
that rather than needing computer clusters capable of
meeting peak needs and thus often leaving excess, unused
capacity, cloud computing more efficiently distributes
computing resources and only requires institutions to pay
for the computing used. In addition, cloud architectures
are potentially more nimble and adaptable to shifting
analysis tools. Cloud based platforms may also facilitate
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inter-institutional collaboration, including sharing of
analytic pipelines.

Alexis Carter, MD
Alexis Carter, Director of Pathology Informatics and
Assistant Professor in the Department of Pathology and
Laboratory Medicine and Department of Biomedical
Informatics at Emory University School of Medicine,
offered insight on transfusion clinical decision support.
In her talk, “transfusion guidelines versus practice: The
impact of clinical decision support tools on transfusion
behavior,” she described work that she and colleagues did
at Emory to improve the utilization of blood products.
Blood products are commonly misused, most often in
the direction of transfusing a patient when not indicated.
At the very least, this puts patients at risk for harm
while engendering unnecessary cost for the institution.
Dr. Carter et al. undertook an effort to understand why
physicians transfuse patients in an ethnographic study
and this is being followed by a study looking at decision
support systems in the EHR that will help encourage
physicians to transfuse according to national[22-24] and
institutional guidelines. Dr. Carter devoted the majority
or her talk to discussing their specific findings which are
unpublished data. Therefore, these findings are reserved
for subsequent publication.

Block 3 Presentations: Technical Strategies and
Methods for Implementing Data Integration and
Decision Suppor t
Ulysses Balis, MD

Ulysses Balis, Associate Professor and Informatics
Director in the Division of Pathology Informatics in the
Department of Pathology in the University of Michigan
Health System, introduced the emerging area of
multi-analyte assays with algorithmic analysis (MAAAs),
in his talk, “Machine-learning-based thiopurine
monitoring and decision support as an exemplar of
encoded data use in clinical settings.”
MAAAs work by applying machine learning or other
algorithms to a panel of individual laboratory test results
from a patient to generate diagnostic information that
the individual results, interpreted in isolation, could
not provide. Among the reasons why MAAAs may be
useful is that the human brain is limited in its ability to
discern complex patterns from high-dimensional data,
such as a panel of results (see description of the talk by
Brian Jackson). In contrast, however, these patterns may
be discernable to computers using machine learning
algorithms. Two widely known examples of MAAAs
include liver fibrosis algorithms[25] and tests for fetal
abnormalities (e.g., the “quad screen”.)
Dr. Balis devoted a substantial portion of his talk to
describing a particular MAAA developed by colleagues
at the University of Michigan to monitor therapy with
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thiopurine medications. Thiopurines, commonly used
to treat inflammatory bowel disease, require monitoring
because they have narrow therapeutic indices and not all
patients respond. Metabolite levels are sometimes assayed
to for use in monitoring but this metabolite testing
is expensive and not optimally predictive of response.
A MAAA developed at the University of Michigan used a
random forest classifier (an established machine learning
technique) to predict patients’ thiopurine responses
based upon a panel of routine hematology and chemistry
analytes. Not only is this MAAA much less expensive,
but actually more accurate in monitoring response, as
compared to the metabolite test. This MAAA has been
described in detail in Waljee et al., 2010.[26]
One challenge to implementing MAAAs and related
approaches is that traditional LISs are incapable
of executing the complex algorithms needed to
integrate the individual results. The thiopurine MAAA
was implemented using an external, distributed
architecture (the LIDDEx System) interfacing with, but
existing outside the LIS. However, to optimally apply
such approaches going forward, LIS vendors will need
to improve their systems’ functionality to facilitate
data extraction and interaction with external systems
and improve their ability to implement advanced data
processing algorithms.

Jason Baron, MD
Jason Baron, Assistant in Pathology at the MGH and
Instructor of Pathology at Harvard Medical School,
presented “Pathology Decision Support Meets Big Data.”
In this talk, he discussed emerging opportunities to
identify novel patterns in clinical and laboratory data that
may enhance decision support and increase the diagnostic
information generated through laboratory testing. He also
noted many of the accompanying challenges.
Dr. Baron began by explaining that in many cases,
groups of patients exhibit wide variability in responses
to treatment or ultimate outcomes, despite presenting
similarly in terms of diagnoses, comorbidities and
other currently known predictors of clinical course.
His hypothesis is that by mining large sets of clinical
and laboratory data, we may be able to identify subtle
patterns that can predict prognosis, response to therapy
or ideal clinical management in ways that standard
manual interpretation of data cannot. Among the
philosophical rationales Dr. Baron provided for this
hypothesis is the reality that the human brain is incapable
of optimally analyzing high-dimensionality data, leaving
many “unexplored” opportunities for refinement in
diagnosis. However, perhaps even more significant is that
identification of subtle patterns requires large sets of
data (see discussion of overfitting below) and even the
busiest clinicians can only see a relatively small number
of patients during the course of their careers. In contrast,
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a computer can “learn” from mining millions of patient
records from a large health system or inter-institutional
data sharing program.
After noting that large data sets will be necessary
to identify complex patterns, Dr. Baron devoted the
majority of his talk to answering the question, “W hy
‘big’ data” and the related issue of the potential tradeoff
between data size and data quality. To answer this
question, he provided a very brief conceptualization of
supervised machine learning using a project to identify
spurious glucose results as an example.[27] In particular,
he discussed the idea of overfitting. Overfitting occurs
when a machine learning model fits to random patterns
within a set of “training” data that do not generalize.
Overfit models “mistake noise for a real pattern” and
will perform better in classifying training data than an
independent set of test data. Overfitting will tend to
increase with the complexity of the model being fit and
decrease with the size of the training data used to fit the
model. Model complexity parallels degrees of freedom
and thus models incorporating many parameters (fit to
high-dimensional data) will tend to be complex and prone
to overfitting. Because these are the types of models we
may wish to fit using pathology data, we will need large
datasets from large health systems and eventually, large
inter-institutional data exchange networks.
Another consideration Dr. Baron discussed is the
potential tradeoff between data size and data quality.
Data quality may be limited by factors including
completeness, accuracy, accessibility and structure.
In the case of structure, there may be a real tradeoff
between size and quality, because although unstructured
data can be manually encoded to a more structured
format, the resources required to do so are roughly
proportional to the size of the dataset. Although
high-quality, high-quantity data would be optimal from
a data mining point of view, in some cases, it is possible
that a very large dataset may be useful even if relatively
low quality. Google Flu Trends[28] is an example in which
high-quality information (influenza trends) is derived
from very high quantity but, in many regards, low
quality data (unstructured flu-related Google internet
searches).

Ramy Arnaout, MD, DPhil
Dr. Ramy Arnaout, Assistant Professor of Pathology and
Associate Director of the Clinical Microbiology Laboratory
at the Beth Israel Deaconess Medical Center (BIDMC)
and faculty in Clinical Informatics at BIDMC and the
Systems Biology PhD program at Harvard Medical School,
discussed the landscape of inappropriate laboratory
testing in medicine in his talk “Clinical Laboratory Data
by the Numbers.” As pathologists look to update the
specialty’s value proposition for the age of big data, a
fitting question is how well clinicians interact with the
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single largest source of data in pathology: Laboratory
testing.
Dr. Arnaout pointed out that laboratory testing is the
single highest-volume medical activity, with over six
billion tests performed each year in the United States
alone. He also noted that the prevailing narrative
at hospitals in regard to laboratory testing is that
unnecessary repeat testing is the crux of the problem and
is bankrupting medicine. He then proceeded to describe
results from a 15-year meta-analysis, in which his group
reviewed over 1.5 million orders covering 46 of the 50
most frequently ordered tests, that suggested that this
narrative is categorically wrong. “Inappropriate laboratory
utilization is widespread, but it’s not where we think,”
he said. Understanding when and how inappropriate
utilization occurs, he argued, gives pathologists a
tremendous opportunity to reshape information flows
to make this high volume medical activity better
serve patients and clinicians. The data presented in
Dr. Arnaout’s talk is available in a recent publication.[29]

Block 4 Presentations: Practical Consideration
and Str ategies to Br ing Big Pictur e Id eas to
Implementable Endeavors
JiYeon Kim, MD, MPH

JiYeon Kim, Physician-in-Charge of Chemistry and
Laboratory Informatics at the Regional Reference
Laboratories of Southern California Permanente
Medical Group, delivered a talk, “Lab Data and Patient
Outcomes.” She began her talk by comparing the
implications of evidence-based decision-making in
medicine, such as treatment options based on lab data,
to driver-less cars. She explained that Google’s tests with
self-driven cars provide evidence that they are far safer
than cars driven by the typical human driver. In fact,
it should be noted that the Google car’s only reported
collision to date was the fault of a human driver who
rear-ended the car driven by the Google computer.
However, people may be much more accepting of errors
made by humans (from whom errors are expected)
than by machines and may be willing to accept a more
error-prone human performing a task over a less-error
prone machine. Similarly, for laboratory clinical decision
support, an algorithm providing clinical advice (or even
an automated diagnosis or treatment) may be held to
a much higher standard than would a person providing
the same function. A consequence of this philosophy is
that health care systems may choose not to implement
decision support systems that fail to reach a standard of
perfection for every patient, even when such algorithms
could clearly improve diagnostic quality or safety for the
population as a whole.
Dr. Kim also argued that laboratories should move
beyond just presenting test results alone, as there are
many instances where the lab data can be prone to
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over-interpretation, potentially leading to inappropriate
treatment or adverse outcomes. For example, studies
have shown some physicians order troponins on patients
indiscriminately and then admit patients with low-level
troponin elevations, even when there is no clinical basis
to suspect cardiac ischemia. In some of these cases, the
clinicians may be failing to interpret the troponins in a
Bayesian context; given a very low pretest likelihood of
cardiac ischemia, even a positive troponin result may
likely be a false positive. Dr. Kim implies that laboratories
could help improve this situation by taking a greater
role in ensuring that troponins be ordered only when
clinically indicated and that they be reported in a way
that incorporates clinical context. Troponins are just one
of many examples fitting this paradigm.
Another point made by Dr. Kim related to how
laboratories have large quantities of structured data
at their disposal; mining this data has the potential
to better identify patterns that may inform and refine
appropriate treatment. Finally, Dr. Kim argues that given
the laboratory’s key role in diagnosing a wide-range of
diseases, the laboratory needs to develop partnerships
through the health care system and particularly with
patients themselves. This may include expanding the
provision of actionable information directly to patients.

Walter Henricks, MD
Walter Henricks, Medical Director of the Center
for Pathology Informatics and Staff Pathologist at
the Pathology and Laboratory Medicine Institute of
the Cleveland Clinic, offered a number of practical
considerations and decision support opportunities in his
talk, “Pathology’s Role in Implementation of Laboratory
Test Order Management in the EHR.” Many of the
opportunities he described are not only possible in the
present, but might also facilitate some of the longer term
goals described in some of the other talks.
Dr. Henricks began by noting that many of the
informatics and decision support challenges we face
are “more than IT ” and really involve “people” and
“processes” as well. He next noted some of the strategies
he and colleagues employ at the Cleveland Clinic within
their Epic EHR and its CPOE capabilities. Among these
are “hard stops” implemented in the CPOE systems to
prevent clinicians from placing duplicate orders on the
same day for certain laboratory tests; overriding these
hard stops requires placing a call to the laboratory. “Soft
stops” are a utilization tool related to hard stops, in which
the ordering provider has the opportunity to override
the alert and proceed with ordering the test. Because of
initially uneven adoption of CPOE and the availability
of process workarounds at community hospitals in its
health system, Cleveland Clinic deployed soft stops as a
lower risk and a more politically viable first step in such
mixed-provider environments.
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Cleveland Clinic has also implemented decision support
rules that restrict the ordering of certain complex and
typically expensive genetic and genomic tests to clinicians
who are “deemed users.” Deemed users mostly consist
of specialists in the disorder(s) for which the test is
appropriately used. Non-deemed users must get approval
from the laboratory, medical genetics, or a deemed user
prior to ordering. For requests referred to the laboratory,
a laboratory-based genetics counselor assists in the review
and a molecular genetic pathologist is the approver.
In addition, the Cleveland Clinic further restricts use
of these tests specifically on inpatients by allowing
the test only if recommended by a medical genetics
consultation. The CPOE system also displays guidance
for pharmacogenomic testing and relevant previous
pharmacogenomic results to providers when they order
certain medications.
Because
“people”
and
“governance”
are
key
considerations in implementing these types of decision
support, Dr. Henricks noted the importance of having
a test utilization committee to determine the decision
support rules and alert criteria used in the CPOE
system. A pathologist chairs this committee, which has
“multidisciplinary” membership including members of
other clinical departments (all department heads are
invited) and IT leadership. The committee provides
recommendations to hospital leadership, including the
Chief Executive Officer, Chief of Staff and Chief of
Medical Operations for support and approval.

Anand Dighe, MD, PhD
Anand Dighe, Associate Pathologist and Director of
the Core Laboratory in the Department of Pathology
at the MGH and Associate Professor of Pathology
at Harvard Medical School, delivered the final talk
of the symposium, “Barriers and Opportunities for
Pathologist-Driven Decision Support.” In it he argued
that expectations for clinical laboratories are too low;
the current bar which simply requires laboratories to
report basic observations and data needs to be raised.
Laboratories should increasingly be looked upon help
guide test selection and provide diagnostic information,
rather than simple observations. W hile meeting these
higher expectations could drastically enhance the value of
laboratory testing, there are numerous barriers to doing
so. Given the sheer volume of laboratory tests, manual
pathologist involvement must be limited to select cases;
in most instances, electronic decision support systems
need to be developed and deployed to provide this
enhanced diagnostic value.
Dr. Dighe specifically described six barriers along
with possible solutions. The first of these barriers was
“Someone else is already doing it.” By this he meant that
at many institutions, the CPOE and other electronic
systems are controlled by non-pathologists; however,
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pathologists need to be involved in or ideally control the
clinical content of the CPOE system for laboratory tests
to enable them to manage test utilization and appropriate
test selection. A related barrier is “we (pathologists) don’t
have the tools to do the job.” With this second barrier,
Dr. Dighe was pointing out that even when pathologists
want to be involved in the content of a CPOE system
and have the administrative authority to do so, their
ability may be technically limited by a need to request
IT resources to make CPOE updates. One solution is for
pathologists to develop middleware applications, such as
the MGH Path Connect System,[30] that allow them to
update the clinical content of the CPOE systems without
involvement of IT staff.
The third barrier discussed is that most laboratories and
health systems now use primarily commercially developed
systems that often leave limited opportunities for
customization. Nonetheless, Dr. Dighe argued that many
of these systems offer “untapped capabilities” meaning
that some apparent limitations may be in a health
system’s understanding or application of its systems and
not in the systems themselves. In addition, when a new
system is being selected or deployed, Dr. Dighe argued
that it is imperative that pathologists be involved early
and throughout the process. The fourth barrier Dr. Dighe
mentioned is “W hy can’t our providers just use the
system properly?” The key here is that laboratories should
not assume that clinicians will properly use whatever
systems they are initially given. It is important to collect
data on how providers interact with the system to make
adjustments and provide additional user education as
indicated.
The fifth barrier is “I can’t get useful reports out of the
system.” By this, Dr. Dighe is cautioning against being
reliant on central hospital or enterprise IT services to
provide a report every time important data is needed from
the LIS or CPOE systems. It is important for pathologists
to have a way to access this data in real time to make
operational improvements and optimally fulfill their
responsibilities. Having to wait in queues (potentially
months long) to get needed data can severely impair
laboratory operations. One solution is for pathologists to
create data marts that store mirrors of data in the LIS
and CPOE systems that pathologists can query as needed
to generate key reports and metrics.
The sixth barrier is the historic perception in some
laboratories that “Once the result is sent to the EHR,
I’m done.” In contrast to this view, Dr. Dighe argued
that laboratories could greatly enhance value by taking
steps to ensure that “actionable” laboratory results are
properly acted upon. “Dropped balls” (laboratory results
not properly follow-up or acted upon) are of particular
concern with information that is time-sensitive, but
is not critical, since critical results are directly called
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to a responsible person. Results viewers that require
responsible clinicians to acknowledge actionable results
with processes to follow-up if acknowledgment does
not occur within a specified period may be useful.
Laboratories need to consider processes and strategies
to monitor and avoid result communication and action
failures.

DISCU SSION
A number of recurrent themes emerged from the
symposium. Perhaps the most pervasive of these related to
the dichotomy between data and diagnostic information [2]
with regard to laboratory testing. In particular, laboratories
currently produce primarily observational data and leave
it to clinicians to integrate these data and convert data
into true diagnostic information. However, the human
brain is not well-equipped to interpret multidimensional
data,[17,18] and laboratory and clinical data typically
exist as large numbers of discrete observations. This
highlights the need for computational systems to convert
laboratory data to information, effectively reducing the
dimensionality of the information that clinicians must
process.
Likewise, there are differences between human talents
and computer abilities; well-designed symbioses between
humans and computers may ultimately optimize
diagnosis. Furthermore, unsupervised statistical analysis
of data alone may not be sufficient and we may instead
need to constrain our analysis though use of mechanistic
physiologic models. We will also need to incorporate
human intuition and domain expertise into our models.
Another facet that emerged related to the often complex
relationship between data and the information that can
derived from it.[26,27] For example, MAAAs use large sets
of laboratory values to provide key information that raw
data alone could not. A corollary to this idea is that much
of the laboratory data currently produced is not fully
converted to information. A key strategy to improving
laboratory diagnosis is to better utilize available data.
However, a challenge will involve identifying patterns
in data without overfitting, or in other words, clearly
discriminating “signal from noise”. Another major theme
from the symposium involved the unique challenges
posed by emerging diagnostic technologies and in
particular, next generation sequencing. In genomics,
the separation between data and information is far
greater than in most traditional areas of diagnostic
testing. W hile with basic laboratory testing, considerable
information can be manually extracted from the relatively
unprocessed data, this is impossible within the context
of next generation sequencing. Raw sequence reads
are useless in diagnosis without further computational
processing, alignment, base calling and variant-calling
with additional and potentially extensive clinical and
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familial correlation for variants that are not already well
defined. Furthermore, interpretation of next generation
sequencing data requires a computer-usable knowledge
base derived from the literature and prior experience
and systems to apply this knowledge to help automate
interpretation. Without this, manual review of identified
variants would be cost prohibitive. Other challenges
with regard to genomics include the consideration that
much of the data generated is of yet to be determined
significance and that the knowledge base is in constant
flux. As with other areas, guiding clinicians as to the
appropriate action to take in response to genomic results
is critical.
The utility of automating various aspects of information
processing was another recurrent theme. For example, a
computational infrastructure may eventually help transform
the fields of pathology and laboratory medicine into
central diagnostic specialties, providing integrative reports
that clearly define precise diagnoses with clear therapeutic
information in many cases. Likewise, laboratory data
could potentially be used to provide overarching objective
evaluations of pathologist and trainee performance as well
as a comprehensive understanding of the value and utility
of various health care services.
A final theme that emerged related to how many of
the barriers to bringing decision support toward reality
are really personnel, political, infrastructural and
administrative challenges rather than technological
limitations. For example, training and educating
pathologists is a key measure in driving this field forward.
Likewise, while superficially a technological consideration,
a key component to developing the “professional LIS”
may lay in building co-development relationships
between pathologists and LIS vendors. Moreover, the
functionality of information systems may be limited by
the knowledge base of the people using them. Likewise,
strong governance and organizational structures are keys
to the success of decision support efforts at large medical
centers.
Both patients and clinicians stand to benefit from the
greater diagnostic precision, optimized test utilization,
improved efficiency and reduced costs that may stem
from enhanced pathology decision support. For example,
pathology decision support could benefit patients through
more rapid or precise diagnosis, allowing them to receive
treatments that are more “personalized,” timely and
clinically optimal. This should in turn improve outcomes,
reduce side-effects from ineffective treatments and reduce
patients’ cost of care. Likewise, physicians may benefit
through improved efficiency, reduced risk of error and
enhanced diagnostic capacity. The improved efficiency
may also provide clinicians with the opportunity to spend
more time interacting with patients and performing other
rewarding clinical activities.

[Downloaded free from http://www.jpathinformatics.org on Friday, September 30, 2016, IP: 128.252.11.235]

JPathol Inform 2014, 1:2

However, the potential benefits of pathology decision
support are not limited to direct patient care. Rather, this
emerging field may also offer new research opportunities
and improve the economics of pathology services. For
example, expanded decision support should generate
novel clinical research questions. In particular, clinical
research will be needed to investigate the optimal
strategies for management of clinical conditions in
the setting of increased diagnostic precision. Likewise,
health systems research will be needed to study the
effects of the decision support systems themselves.
Similarly, the improved ability to convert raw genomic
data into clinically actionable information will facilitate
translational genomic research. Basic science researchers
may be called upon to investigate the biologic or
physiologic mechanisms underlying newly identified
patterns within clinical data. Finally, by enhancing the
value of laboratory services and helping to demonstrate
the contribution that laboratory testing provides
to patient care, electronic decision support systems
could improve the economics of pathology. Indeed,
as accountable care organizations expand and provide
health systems with a single limited pool of resources,[16]
it may be particularly incumbent upon pathologists to
demonstrate the value of their services.
Overall, the symposium illustrated that, while pathology
decision support is a field still in its infancy, it is a field
with tremendous opportunity and potential that is moving
quickly. There is a clear need for inter-institutional
collaboration to solve the technical, infrastructural and data
acquisition challenges and to support LIS and EHR vendors
in developing systems that can support emerging decision
support strategies. We look forward to holding a follow-up
symposium on this topic to discuss interim progress.
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